EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieMixed-Methods-StudieOpen Access · CC BY 4.0

The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysis

Vrinda Saraff iD, Pedro Arango Sancho, Justine Bacchetta, Annemieke M Boot iD, Christine Burren, Amish Chinoy, Poonam Dharmaraj, Maria Amelia Gómez Llorente iD, Juan David González Rodríguez iD, Iva Gueorguieva iD, Elin Haf Davies, Wesley Hayes und 10 weitere

PLOS One · 20.03.2026 · 21 (3) · e0344902

DOI: 10.1371/journal.pone.0344902 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS One, online erschienen am 20.03.2026. Verfasst von Vrinda Saraff und 21 weiteren Autor:innen. Beteiligte Einrichtung: Birmingham Women's and Children's Hospital, Birmingham, United Kingdom. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Bone Development, Familial Hypophosphatemic Rickets. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyowa Kirin International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

X-linked hypophosphataemia is a rare, genetic, lifelong disorder caused by phosphate-regulating endopeptidase homologue X-linked pathogenic variants and, if left untreated, is associated with a progressive accumulation of musculoskeletal manifestations. Burosumab is a fully human monoclonal antibody that targets circulating fibroblast growth factor 23 and directly inhibits its activity, thereby correcting the abnormal phosphate homoeostasis in people with X-linked hypophosphataemia (XLH). The efficacy and safety of burosumab has been demonstrated in a programme of clinical trials in children and adults. Few data describe the experience of adolescents with XLH receiving burosumab treatment before and after skeletal growth ends. This prospective, multicentre, mixed-methods study described the lived experience of adolescents with XLH treated with burosumab at the end of skeletal growth (NCT05181839). Using patient-reported outcomes, wearable devices, and interviews, we found low median symptom severity scores for pain (0.00), stiffness (0.00), and fatigue (1.75) on a 0–10 scale. Symptoms were usually triggered by physical activity but rarely interfered with daily life. Some adolescents reported emotional concerns related to XLH and treatment transition. These insights can inform patient support during transition to adult care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedBone DevelopmentFamilial Hypophosphatemic RicketsAdolescentFemaleHumansMaleFibroblast Growth Factor-23Patient Reported Outcome MeasuresProspective Studies

Substanzen

Antibodies, Monoclonal, HumanizedburosumabFibroblast Growth Factor-23

Autor:innen und Institutionen

  • Birmingham Women's and Children's Hospital, Birmingham, United Kingdom.
  • Sant Joan de Déu Barcelona Hospital, Barcelona, Spain.
  • Hospices Civils de Lyon, INSERM1033 Research Unit, Lyon, France.
  • University Medical Center Groningen, University of Groningen, The Netherlands.
  • University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
  • Royal Manchester Children's Hospital, Manchester, United Kingdom.

ORCID-Profile: Vrinda Saraff, Annemieke M Boot, Maria Amelia Gómez Llorente, Juan David González Rodríguez, Iva Gueorguieva, Angela Williams

Förderung

  • Kyowa Kirin International

Zitieren

APA

Saraff, V., Sancho, P. A., Bacchetta, J., Boot, A. M., Burren, C., Chinoy, A., Dharmaraj, P., Llorente, M. A. G., Rodríguez, J. D. G., Gueorguieva, I., Davies, E. H., Hayes, W., Komarzynski, S., Duro, H. R., Rylands, A. J., Sandilands, K., Williams, A., Hardie, E., Ishii, H., …, & Linglart, A. (2026). The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysis. PLOS One, 21(3), e0344902. https://doi.org/10.1371/journal.pone.0344902

Vancouver

Saraff V, Sancho PA, Bacchetta J, Boot AM, Burren C, Chinoy A, et al. The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysis. PLOS One. 2026;21(3):e0344902. doi:10.1371/journal.pone.0344902

BibTeX
@article{Saraff2026,
  author = {Saraff, Vrinda and Sancho, Pedro Arango and Bacchetta, Justine and Boot, Annemieke M and Burren, Christine and Chinoy, Amish and Dharmaraj, Poonam and Llorente, Maria Amelia Gómez and Rodríguez, Juan David González and Gueorguieva, Iva and Davies, Elin Haf and Hayes, Wesley and Komarzynski, Sandra and Duro, Héctor Ríos and Rylands, Angela J and Sandilands, Kerry and Williams, Angela and Hardie, Emily and Ishii, Haruka and Schnabel, Dirk and Selveindran, Santhani M and Linglart, Agnès},
  title = {The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysis},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {e0344902},
  doi = {10.1371/journal.pone.0344902}
}
Kostenlos starten →